Skip to main content
Top

08-06-2024 | Arterial Diseases | Ischemic Heart Disease (D Mukherjee, Section Editor)

Systematic Review on Role of Drug Eluting Stent (DES) Versus Drug-Coated Balloon (DCB) in Small Vessel Coronary Artery Disease

Authors: Motisola Mutema, Vishnu Shenoy, Partha Sardar, Sahil Parikh, Saurav Chatterjee

Published in: Current Cardiology Reports

Login to get access

Abstract

Purpose of Review

This review aims to explain the current advancements in the treatment modalities for small vessel coronary artery disease (SVCAD) and de novo lesions post-percutaneous coronary intervention (PCI), focusing on drug-coated stents (DES) and drug-coated balloons (DCB). Its goal is to address the lack of standards in the management of these lesions and to assess the potential of DCB as a preferential treatment strategy over DES in the long term.

Recent Findings

Technological advancements have improved drug-eluting stents (DES) and drug-coated balloons (DCB) which offer a more promising avenue for managing SVCAD. According to new data, DCBs, initially recognized for their efficacy in preventing restenosis within three to five years of stent placement, may offer superior outcomes compared to DES in certain clinical scenarios.

Summary

This review shows that DCBs have a favorable therapeutic profile in the treatment of SVCAD, and they could be considered as an alternative to DES. Although the initial data is compelling, definitive conclusions cannot be met without further large-scale, long-term clinical trials. The implication of these findings suggests a shift in the future of SVCAD management and requires additional research to substantiate the long-term benefits of DCB use in SVCAD. Should ongoing and future studies corroborate the current evidence, DCB could emerge as the standard of care for SVCAD, significantly influencing clinical practices and future research.
Literature
1.
go back to reference Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23.CrossRefPubMed Malakar AKr, Choudhury D, Halder B, Paul P, Uddin A, Chakraborty S. A review on coronary artery disease, its risk factors, and therapeutics. J Cell Physiol. 2019;234(10):16812–23.CrossRefPubMed
2.
go back to reference Agostoni P, Biondi-Zoccai GGL, Gasparini GL, Anselmi M, Morando G, Turri M, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005;26(9):881–9.CrossRefPubMed Agostoni P, Biondi-Zoccai GGL, Gasparini GL, Anselmi M, Morando G, Turri M, et al. Is bare-metal stenting superior to balloon angioplasty for small vessel coronary artery disease? Evidence from a meta-analysis of randomized trials. Eur Heart J. 2005;26(9):881–9.CrossRefPubMed
3.
go back to reference Wybraniec MT, Bańka P, Bochenek T, Roleder T, Mizia-Stec K. Small vessel coronary artery disease: How small can we go with myocardial revascularization? Cardiol J. 2021;28(5):767–78. Findings from this meta-analysis suggest that DCB is an alternative to DES shows similar efficacy between 2.0 and 2.5mm.CrossRefPubMed Wybraniec MT, Bańka P, Bochenek T, Roleder T, Mizia-Stec K. Small vessel coronary artery disease: How small can we go with myocardial revascularization? Cardiol J. 2021;28(5):767–78. Findings from this meta-analysis suggest that DCB is an alternative to DES shows similar efficacy between 2.0 and 2.5mm.CrossRefPubMed
4.
go back to reference Giannini F, Khokhar AA, Albani S. Percutaneous Intervention in Small-Vessel Coronary Disease. JACC Cardiovasc Interv. 2020;13(7):805–7.CrossRefPubMed Giannini F, Khokhar AA, Albani S. Percutaneous Intervention in Small-Vessel Coronary Disease. JACC Cardiovasc Interv. 2020;13(7):805–7.CrossRefPubMed
5.
go back to reference Lobato EB. Care of the patient with coronary stents undergoing noncardiac surgery. Essentials of Cardiac Anesthesia for Noncardiac Surgery. 2019;33–69. Lobato EB. Care of the patient with coronary stents undergoing noncardiac surgery. Essentials of Cardiac Anesthesia for Noncardiac Surgery. 2019;33–69.
6.
go back to reference Short L, La VT, Patel M, Pai RG. Primary and secondary prevention of CAD: A review. Int J Angiol Off Pub Inte College Angiol Inc. 2022;31(1):16–26. Short L, La VT, Patel M, Pai RG. Primary and secondary prevention of CAD: A review. Int J Angiol Off Pub Inte College Angiol Inc. 2022;31(1):16–26.
7.
go back to reference Cortese B, Kalkat H, Gurbir B, Sandeep B. The evolution and revolution of drug coated balloons in coronary angioplasty: An up‐to‐date review of literature data. Catheter Cardiovas Interv. 2023;102(6):1069–77.CrossRef Cortese B, Kalkat H, Gurbir B, Sandeep B. The evolution and revolution of drug coated balloons in coronary angioplasty: An up‐to‐date review of literature data. Catheter Cardiovas Interv. 2023;102(6):1069–77.CrossRef
8.
go back to reference Anghel L, Bogdan-Sorin T, Andreea L, Zăvoi A, Clément A, Roungos AE, et al. Patient-related factors predicting stent thrombosis in percutaneous coronary interventions. J Clin Med. 2023;12(23):7367–7.CrossRefPubMedPubMedCentral Anghel L, Bogdan-Sorin T, Andreea L, Zăvoi A, Clément A, Roungos AE, et al. Patient-related factors predicting stent thrombosis in percutaneous coronary interventions. J Clin Med. 2023;12(23):7367–7.CrossRefPubMedPubMedCentral
9.
go back to reference Parfrey S, Siu V, Graham J, Vijayaraghavan R, Li C, Pang J, et al. Evaluation and management of drug-eluting stent in-stent restenosis. Curr Opin Cardiol. 2023;38(5):433–40.CrossRefPubMed Parfrey S, Siu V, Graham J, Vijayaraghavan R, Li C, Pang J, et al. Evaluation and management of drug-eluting stent in-stent restenosis. Curr Opin Cardiol. 2023;38(5):433–40.CrossRefPubMed
10.
go back to reference Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36(2):158–68.CrossRefPubMed Kuramitsu S, Sonoda S, Ando K, Otake H, Natsuaki M, Anai R, et al. Drug-eluting stent thrombosis: current and future perspectives. Cardiovasc Interv Ther. 2021;36(2):158–68.CrossRefPubMed
11.
go back to reference Marei I, Ahmetaj-Shala B, Triggle CR. Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in-stent thrombosis in diabetes. Front Pharmacol. 2022;13. Marei I, Ahmetaj-Shala B, Triggle CR. Biofunctionalization of cardiovascular stents to induce endothelialization: Implications for in-stent thrombosis in diabetes. Front Pharmacol. 2022;13.
12.
go back to reference Ochijewicz D, Tomaniak M, Opolski G, Kochman J. Inflammation as a determinant of healing response after coronary stent implantation. Int J Cardiovasc Imaging. 2021;37(3):791–801.CrossRefPubMedPubMedCentral Ochijewicz D, Tomaniak M, Opolski G, Kochman J. Inflammation as a determinant of healing response after coronary stent implantation. Int J Cardiovasc Imaging. 2021;37(3):791–801.CrossRefPubMedPubMedCentral
13.
go back to reference Saito N, Mori Y, Komatsu T. Influence of stent flexibility on artery wall stress and wall shear stress in bifurcation lesions. Med Dev Evid Res. 2020;13:365–75.CrossRef Saito N, Mori Y, Komatsu T. Influence of stent flexibility on artery wall stress and wall shear stress in bifurcation lesions. Med Dev Evid Res. 2020;13:365–75.CrossRef
14.
go back to reference Lee SJ, Choi DW, Suh Y, Hong S, Ahn C, Kim JS, et al. Long-term clinical outcomes between biodegradable and durable polymer drug-eluting stents: A nationwide cohort study. Front Cardiovasc Med. 2022;29:9. Lee SJ, Choi DW, Suh Y, Hong S, Ahn C, Kim JS, et al. Long-term clinical outcomes between biodegradable and durable polymer drug-eluting stents: A nationwide cohort study. Front Cardiovasc Med. 2022;29:9.
15.
go back to reference Jakubiak GK, Pawlas N, Cieślar G, Stanek A. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Public Health. 2021;18(22):11970.CrossRefPubMedPubMedCentral Jakubiak GK, Pawlas N, Cieślar G, Stanek A. Pathogenesis and clinical significance of in-stent restenosis in patients with diabetes. Int J Environ Res Public Health. 2021;18(22):11970.CrossRefPubMedPubMedCentral
16.
go back to reference Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation. 2020. Khan SU, Singh M, Valavoor S, Khan MU, Lone AN, Khan MZ, et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation. 2020.
17.
go back to reference Cheng HM, Chiou LJ, Chen TC, Sung SH, Chen CH, Lang HC. Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease—A five-year follow-up study. Health Policy. 2019;123(2):229–34. Cheng HM, Chiou LJ, Chen TC, Sung SH, Chen CH, Lang HC. Real-world cost-effectiveness of drug-eluting stents vs. bare-metal stents for coronary heart disease—A five-year follow-up study. Health Policy. 2019;123(2):229–34.
18.
go back to reference Chioncel V, Andrei CL, Brezeanu R, Sinescu C, Avram A, Tatu AL. Some perspectives on hypersensitivity to coronary stents. Int J Gen Med. 2021;14:4327–36.CrossRefPubMedPubMedCentral Chioncel V, Andrei CL, Brezeanu R, Sinescu C, Avram A, Tatu AL. Some perspectives on hypersensitivity to coronary stents. Int J Gen Med. 2021;14:4327–36.CrossRefPubMedPubMedCentral
20.
go back to reference Hu W, Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front Bioeng Biotechnol. 2022;15:10. Hu W, Jiang J. Hypersensitivity and in-stent restenosis in coronary stent materials. Front Bioeng Biotechnol. 2022;15:10.
21.
go back to reference Zong J, He Q, Liu Y, Qiu M, Wu J, Hu B. Advances in the development of biodegradable coronary stents: A translational perspective. Mater Today Bio. 2022;1(16):100368.CrossRef Zong J, He Q, Liu Y, Qiu M, Wu J, Hu B. Advances in the development of biodegradable coronary stents: A translational perspective. Mater Today Bio. 2022;1(16):100368.CrossRef
22.
go back to reference Silverio A, Buccheri S, Venetsanos D, Alfredsson J, Lagerqvist B, Persson J, et al. Percutaneous treatment and outcomes of small coronary vessels: A SCAAR report. JACC Cardiovasc Interv. 2020;13(7):793–804.CrossRefPubMed Silverio A, Buccheri S, Venetsanos D, Alfredsson J, Lagerqvist B, Persson J, et al. Percutaneous treatment and outcomes of small coronary vessels: A SCAAR report. JACC Cardiovasc Interv. 2020;13(7):793–804.CrossRefPubMed
23.
go back to reference Teleb M, Wardi M, Gosavi S, et al. Paclitaxel-coated balloons: review of a promising interventional approach to preventing restenosis in femoropopliteal arteries. Int J Angiol. 2016;25(2):75–80.PubMed Teleb M, Wardi M, Gosavi S, et al. Paclitaxel-coated balloons: review of a promising interventional approach to preventing restenosis in femoropopliteal arteries. Int J Angiol. 2016;25(2):75–80.PubMed
24.
go back to reference Zhao H, Miao R, Lin F, Zhao G. Drug-coated balloon in primary percutaneous coronary intervention. J Interv Cardiol. 2023;26(2023):1–6.CrossRef Zhao H, Miao R, Lin F, Zhao G. Drug-coated balloon in primary percutaneous coronary intervention. J Interv Cardiol. 2023;26(2023):1–6.CrossRef
25.
go back to reference M. Rizwan Sohail, Patel P, Sidharth Midha, Shukla S, Divyanshu Dhamija, Bello A, et al. Identifying the Incidence, predictors, outcomes, and prevention of stent thrombosis (st) in post-percutaneous coronary revascularization patients with drug-eluting stents (des): A systematic review. Cureus. 2023. M. Rizwan Sohail, Patel P, Sidharth Midha, Shukla S, Divyanshu Dhamija, Bello A, et al. Identifying the Incidence, predictors, outcomes, and prevention of stent thrombosis (st) in post-percutaneous coronary revascularization patients with drug-eluting stents (des): A systematic review. Cureus. 2023.
26.
go back to reference Rykowska I, Nowak I, Nowak R. Drug-eluting stents and balloons—materials, structure designs, and coating techniques: a review. Molecules. 2020;25(20):4624.CrossRefPubMedPubMedCentral Rykowska I, Nowak I, Nowak R. Drug-eluting stents and balloons—materials, structure designs, and coating techniques: a review. Molecules. 2020;25(20):4624.CrossRefPubMedPubMedCentral
27.
go back to reference Woolford SE, Tran M, Yoda C, Berk Öktem, NguyenPho A, McDermott MK, et al. Studying the effect of drug-to-excipient ratio on drug release profile for drug coated balloons. Int J Pharm. 2022;620:121749–9. Woolford SE, Tran M, Yoda C, Berk Öktem, NguyenPho A, McDermott MK, et al. Studying the effect of drug-to-excipient ratio on drug release profile for drug coated balloons. Int J Pharm. 2022;620:121749–9.
28.
go back to reference Filippo Z, Verdoia M, Carmen M, Zucchelli F, Borghesi M, Rognoni A, et al. Drug coated balloon in the treatment of de novo coronary artery disease: a narrative review. J Clinl Med. 2023;12(11):3662–2.CrossRef Filippo Z, Verdoia M, Carmen M, Zucchelli F, Borghesi M, Rognoni A, et al. Drug coated balloon in the treatment of de novo coronary artery disease: a narrative review. J Clinl Med. 2023;12(11):3662–2.CrossRef
29.
go back to reference Chang GH, Azar DA, Lyle C, Chitalia VC, Shazly T, Kolachalama VB. Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy. Sci Rep. 2019;(1). Chang GH, Azar DA, Lyle C, Chitalia VC, Shazly T, Kolachalama VB. Intrinsic coating morphology modulates acute drug transfer in drug-coated balloon therapy. Sci Rep. 2019;(1).
30.
go back to reference Giannini F, Latib A, Jabbour RJ, Costopoulos C, Chieffo A, Carlino M, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients – results from the BELLO (balloon elution and late loss optimization) trial. Cardiovasc Revascular Med. 2017;(1):4–9. Diabetes does not appear to have a negative impact on the efficacy of DEB in small vessels, which were associated with better angiographic outcomes at 6 months compared to PEB in this complex subgroup. Giannini F, Latib A, Jabbour RJ, Costopoulos C, Chieffo A, Carlino M, et al. Comparison of paclitaxel drug-eluting balloon and paclitaxel-eluting stent in small coronary vessels in diabetic and nondiabetic patients – results from the BELLO (balloon elution and late loss optimization) trial. Cardiovasc Revascular Med. 2017;(1):4–9. Diabetes does not appear to have a negative impact on the efficacy of DEB in small vessels, which were associated with better angiographic outcomes at 6 months compared to PEB in this complex subgroup.
31.
go back to reference Basavarajaiah S, Kalkat H, Bhatia G, Cortese B. How to perform a successful drug-coated balloon angioplasty? tips and tricks. Catheter Cardiovasc Interv. 2023;102(7):1238–57.CrossRefPubMed Basavarajaiah S, Kalkat H, Bhatia G, Cortese B. How to perform a successful drug-coated balloon angioplasty? tips and tricks. Catheter Cardiovasc Interv. 2023;102(7):1238–57.CrossRefPubMed
32.
go back to reference Zhang Y, Zhang X, Dong Q, Chen D, Xu Y, Jiang J. Duration of dual antiplatelet therapy after implantation of drug-coated balloon. Front Cardiovasc Med. 2021;1:8. Zhang Y, Zhang X, Dong Q, Chen D, Xu Y, Jiang J. Duration of dual antiplatelet therapy after implantation of drug-coated balloon. Front Cardiovasc Med. 2021;1:8.
33.
go back to reference Dash D, Mody R, Ahmed N, Malan SR, Mody B. Drug-coated balloon in the treatment of coronary bifurcation lesions: A hope or hype? Indian Heart J. 2022;74(6):450–7.CrossRefPubMedPubMedCentral Dash D, Mody R, Ahmed N, Malan SR, Mody B. Drug-coated balloon in the treatment of coronary bifurcation lesions: A hope or hype? Indian Heart J. 2022;74(6):450–7.CrossRefPubMedPubMedCentral
34.
go back to reference Yang X, Lu W, Pan L, Han Z, Pan S, Wang X, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. Front Cardiovasc Med. 2022;23:9. Yang X, Lu W, Pan L, Han Z, Pan S, Wang X, et al. Long-term outcomes of drug-coated balloons in patients with diffuse coronary lesions. Front Cardiovasc Med. 2022;23:9.
35.
go back to reference Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am College Cardiol. 2020;75(21):2664–78. DES In-stent restenosis associated with higher rates of treatment failure. DCB angioplasty and repeat stenting with DES are similarly effective. Giacoppo D, Alfonso F, Xu B, Claessen BEPM, Adriaenssens T, Jensen C, et al. Drug-coated balloon angioplasty versus drug-eluting stent implantation in patients with coronary stent restenosis. J Am College Cardiol. 2020;75(21):2664–78. DES In-stent restenosis associated with higher rates of treatment failure. DCB angioplasty and repeat stenting with DES are similarly effective.
36.
go back to reference Wang X, Yang X, Liu W, Pan L, Han Z, Pan S, et al. Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo coronary chronic total occlusion intervention: A multicenter observational study. Front Cardiovasc Med. 2023;3:10. Wang X, Yang X, Liu W, Pan L, Han Z, Pan S, et al. Long-term outcomes of less drug-eluting stents by the use of drug-coated balloons in de novo coronary chronic total occlusion intervention: A multicenter observational study. Front Cardiovasc Med. 2023;3:10.
37.
go back to reference Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. 2023;38(2):166–76. Muramatsu T, Kozuma K, Tanabe K, Morino Y, Ako J, Nakamura S, et al. Clinical expert consensus document on drug-coated balloon for coronary artery disease from the Japanese Association of Cardiovascular Intervention and Therapeutics. 2023;38(2):166–76.
38.
go back to reference Liu L, Liu W, Wang X, Pan L, Wang X, Zheng X, et al. Short-term outcomes of drug-coated balloon versus drug-eluting stent for de novo saphenous vein graft lesions in coronary heart disease. Front Cardiovasc Med. 2023;6:10. Liu L, Liu W, Wang X, Pan L, Wang X, Zheng X, et al. Short-term outcomes of drug-coated balloon versus drug-eluting stent for de novo saphenous vein graft lesions in coronary heart disease. Front Cardiovasc Med. 2023;6:10.
39.
go back to reference Ioannis M, Gunawardena T, Corballis N, Tsampasian V, Vassiliou V, Eccleshall S, et al. Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease intervention. Eur Heart J. 2023;44(2). Ioannis M, Gunawardena T, Corballis N, Tsampasian V, Vassiliou V, Eccleshall S, et al. Cost effectiveness analysis of drug coated balloon only angioplasty for de novo coronary artery disease intervention. Eur Heart J. 2023;44(2).
40.
go back to reference Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391–402.CrossRefPubMed Jeger RV, Eccleshall S, Wan Ahmad WA, Ge J, Poerner TC, Shin ES, et al. Drug-coated balloons for coronary artery disease: third report of the international DCB consensus group. JACC Cardiovasc Interv. 2020;13(12):1391–402.CrossRefPubMed
41.
go back to reference Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am College Cardiol. 2012;60(24):2473–80.CrossRef Latib A, Colombo A, Castriota F, Micari A, Cremonesi A, De Felice F, et al. A randomized multicenter study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: the BELLO (Balloon Elution and Late Loss Optimization) study. J Am College Cardiol. 2012;60(24):2473–80.CrossRef
42.
go back to reference Khanal S. A randomized multicentre study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: The BELLO (Balloon Elution and Late Loss Optimization) study. Indian Heart J. 2013;65(2):220–1.CrossRefPubMedCentral Khanal S. A randomized multicentre study comparing a paclitaxel drug-eluting balloon with a paclitaxel-eluting stent in small coronary vessels: The BELLO (Balloon Elution and Late Loss Optimization) study. Indian Heart J. 2013;65(2):220–1.CrossRefPubMedCentral
43.
go back to reference Tian J, Tang Y, Qiao S, Su X, Chen Y, Jin Z, et al. Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. Catheter Cardiovasc Interv Off J Soc Cardiac Angiogr Interv. 2020;95(1):587–97.CrossRef Tian J, Tang Y, Qiao S, Su X, Chen Y, Jin Z, et al. Two-year follow-up of a randomized multicenter study comparing a drug-coated balloon with a drug-eluting stent in native small coronary vessels: The RESTORE Small Vessel Disease China trial. Catheter Cardiovasc Interv Off J Soc Cardiac Angiogr Interv. 2020;95(1):587–97.CrossRef
44.
go back to reference Felbel D, Bozic F, Mayer B, Krohn-Grimberghe M, Paukovitsch M, d’Almeida S, et al. Drug-coated balloon: an effective alternative to stent strategy in small-vessel coronary artery disease—a meta-analysis. Front Cardiovasc Med. 2023;21(10). Felbel D, Bozic F, Mayer B, Krohn-Grimberghe M, Paukovitsch M, d’Almeida S, et al. Drug-coated balloon: an effective alternative to stent strategy in small-vessel coronary artery disease—a meta-analysis. Front Cardiovasc Med. 2023;21(10).
46.
go back to reference Cortese B, Testa G, Rivero F, Erriquez A, Alfonso F. Long-term outcome of drug-coated balloon vs drug-eluting stent for small coronary vessels. JACC Cardiovasc Interv. 2023. Cortese B, Testa G, Rivero F, Erriquez A, Alfonso F. Long-term outcome of drug-coated balloon vs drug-eluting stent for small coronary vessels. JACC Cardiovasc Interv. 2023.
47.
go back to reference Cortese B, Di Palma G, Guimaraes MG, Piraino D, Orrego PS, Buccheri D, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease. JACC Cardiovasc Interv. 2020;13(24):2840–9. In this multicenter randomized clinical trial in patients with de novo SVD lesions, a new-generation DCB was found superior to EES in terms of late lumen loss as the angiographic pattern and comparable in terms of clinical outcome. Cortese B, Di Palma G, Guimaraes MG, Piraino D, Orrego PS, Buccheri D, et al. Drug-coated balloon versus drug-eluting stent for small coronary vessel disease. JACC Cardiovasc Interv. 2020;13(24):2840–9. In this multicenter randomized clinical trial in patients with de novo SVD lesions, a new-generation DCB was found superior to EES in terms of late lumen loss as the angiographic pattern and comparable in terms of clinical outcome.
48.
go back to reference Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023;44(15):1343–57.CrossRefPubMed Giacoppo D, Alvarez-Covarrubias HA, Koch T, Cassese S, Xhepa E, Kessler T, et al. Coronary artery restenosis treatment with plain balloon, drug-coated balloon, or drug-eluting stent: 10-year outcomes of the ISAR-DESIRE 3 trial. Eur Heart J. 2023;44(15):1343–57.CrossRefPubMed
49.
go back to reference Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100(2):153–9.CrossRefPubMed Cassese S, Byrne RA, Tada T, Pinieck S, Joner M, Ibrahim T, et al. Incidence and predictors of restenosis after coronary stenting in 10 004 patients with surveillance angiography. Heart. 2014;100(2):153–9.CrossRefPubMed
50.
go back to reference Bülüç F, Ağırbaş İ, Tulunay Kaya C. Cost effectiveness analysis of stents used in treatment of coronary artery disease. Balkan Med J. 2019. Bülüç F, Ağırbaş İ, Tulunay Kaya C. Cost effectiveness analysis of stents used in treatment of coronary artery disease. Balkan Med J. 2019.
51.
go back to reference Yeh RW. Primary outcomes of a pivotal multicenter randomized trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis. Presented at: TCT 2023. October 25, 2023. San Francisco, CA. Yeh RW. Primary outcomes of a pivotal multicenter randomized trial comparing the AGENT paclitaxel-coated balloon with conventional balloon angioplasty for in-stent restenosis. Presented at: TCT 2023. October 25, 2023. San Francisco, CA.
Metadata
Title
Systematic Review on Role of Drug Eluting Stent (DES) Versus Drug-Coated Balloon (DCB) in Small Vessel Coronary Artery Disease
Authors
Motisola Mutema
Vishnu Shenoy
Partha Sardar
Sahil Parikh
Saurav Chatterjee
Publication date
08-06-2024
Publisher
Springer US
Published in
Current Cardiology Reports
Print ISSN: 1523-3782
Electronic ISSN: 1534-3170
DOI
https://doi.org/10.1007/s11886-024-02077-8
Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin
Prof. Florian Limbourg
Prof. Anoop Chauhan
Developed by: Springer Medicine